NCT00209079View on ClinicalTrials.gov

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Gastric Adenocarcinoma

Interventions

DRUG

Gleevec, Taxotere

Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Emory University

OTHER

NCT00209079 - Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma | Biotech Hunter | Biotech Hunter